ライフサイエンスコーパス: base treatment

1 tive intramolecular 1,5-H shift pathway upon base treatment.

2 receiving NNRTI-based and 20 receiving LPV/r-based treatment.

3 rameters and fewer dyslipidemia AEs than EFV-based treatment.

4 sis and 58% had received previous interferon-based treatment.

5 ained virologic response to prior interferon-based treatment.

6 a mean of 4.8 years of losartan- or atenolol-based treatment.

7 m of AN for which there is no known evidence-based treatment.

8 hat may make them ineligible for fludarabine-based treatment.

9 D OCT, which may increase frequency of fluid-based treatment.

10 ith a greater likelihood of response to cell-based treatment.

11 oblem that continues to challenge medication-based treatment.

12 , randomly assigned to losartan- or atenolol-based treatment.

13 ithm-based treatment, or nurse-led algorithm-based treatment.

14 ive and clinical issues in videoconferencing-based treatment.

15 th EBV-related PTLD survived after rituximab-based treatment.

16 ticipants, and 84 (22%) commenced interferon-based treatment.

17 of drug and the need for ancillary non-drug-based treatment.

18 and tissue disruption by means of cavitation-based treatment.

19 verse outcome and resistance to chemotherapy-based treatment.

20 the known natural history of ROP vs evidence-based treatment.

21 achieved suppression with protease-inhibitor-based treatment.

22 a strong predictor of response to interferon-based treatment.

23 their high prevalence and lack of mechanism-based treatments.

24 ilitate the development of improved antibody-based treatments.

25 ral veterans from engaging in these evidence-based treatments.

26 each of these classes of selective antibody-based treatments.

27 nsplant practices rather than immunoglobulin-based treatments.

28 for in vitro studies and as a source of cell-based treatments.

29 patients who are ineligible for fludarabine-based treatments.

30 the composters changed in response to the Ag-based treatments.

31 e quality by quantifying the use of evidence-based treatments.

32 by use of exogenous pharmacological or cell-based treatments.

33 ed in primary care alongside other evidenced based treatments.

34 ied for the improvement of TCR-gene transfer-based treatments.

35 studying cell behaviour under different drug-based treatments.

36 he treatment may be an alternative to photon-based treatments.

37 ceptor protein by traditional pharmaceutical-based treatments.

38 assessing other chemotherapies or radiation-based treatments.

39 n comparing an mTOR-I with a non-mTOR-I (CNI based) treatment.

40 isease were more likely to receive guideline-based treatment (96%) than patients with stage II (low r

41 roups have followed the paradigm of response-based treatment adaptation and toxicity sparing through

42 nt state and remaining challenges of imaging-based treatment adaptation in radiation oncology.

43 ng nevirapine-exposed children to nevirapine-based treatment after effective suppression of virus rep

44 Lacritin might be a useful biotechnology-based treatment agent against ocular surface diseases wh

45 luR5 may be a promising target for mechanism-based treatments aimed at mitigating this disorder.

46 IA and EPOS provide clinicians with evidence-based treatment algorithms for allergic rhinitis (AR) an

47 ve been used to treat children, but evidence-based treatment algorithms for children are lacking.

48 the synthesis, including high sensitivity to base treatment and the instability of glycopeptides with

49 inform on development of monoclonal antibody-based treatments and a universal flu vaccine for all inf

50 d clinical trials indicate that transference-based treatments and alternative treatments work equally

51 e III trial comparing different lenalidomide-based treatments and received induction with lenalidomid

52 Clinical trials to support evidence-based treatments and the development of disease-specific

53 sorders, our results suggest that metabolism-based treatments and/or metabolic substrates might repre

54 F pathology and the efforts to develop miRNA-based treatments and/or to consider miRNAs as biomarkers

55 tcomes, causes and pathophysiology, evidence-based treatment, and a call for action.

56 rldwide, who received primary amphotericin B-based treatment, and were analysed for day-42 all-cause

57 f smoke inhalation injury, the best evidence-based treatments, and challenges and future directions i

58 preoperative planning, intraoperative image-based treatments, and postoperative care.

59 son engagement session, delivery of evidence-based treatments, and regular follow-up by master's leve

60 ure directions include the use of new immune-based treatments (antibodies or cellular-based therapies

61 However, transference-based treatments appear to be much more effective with r

62 TE, a comprehensive, multidisciplinary, team-based treatment approach for first-episode psychosis des

63 fter stroke, providing an effective evidence-based treatment approach in this population.

64 Prompt recognition and an evidence-based treatment approach is the key to successfully mana

65 Community-based treatment approaches are important to reduce the a

66 These data support development of eCB-based treatment approaches for mood and anxiety disorder

67 Responses to alpha interferon (IFN-alpha)-based treatment are dependent on both host and viral fac

68 prior relapser patients receiving telaprevir-based treatment are eligible for shorter, 24-week total

69 ecurrence, outcomes after fluorouracil (FU) -based treatment are expected to have improved over time

70 Evidence-based treatments are available for patients with active

71 No evidence-based treatments are available to reduce this risk behav

72 ) is a hematological cancer for which immune-based treatments are currently in development.

73 For genotype 1, sofosbuvir-based treatments are not cost-effective compared to Viek

74 he origins of PCOS remain unknown, mechanism-based treatments are not feasible and current management

75 Current anti-MPM chemotherapy-based treatments are only marginally effective, and long

76 oaches, such as vaccines and oncolytic virus-based treatments-are being investigated.

77 athway, which suggests the potential for APC-based treatment as a strategy for structural repair in t

78 We review the rapidly emerging role of GLP-1 based treatments as well as the future for new drugs bas

79 to focus on improving the rates of evidence-based treatment at sites with high proportions of uninsu

80 e able to analyze the effect of a bortezomib-based treatment before and after autologous stem cell tr

81 sy during consideration for interferon-alpha based treatment between 1992 and 2007.

82 inical management practices, possible gender-based treatment bias, and the need to improve testing fo

83 or development and testing of novel evidence-based treatments, both trauma-focused and non-trauma-foc

84 first attempts to implement novel mechanism-based treatments brought rather disappointing results, w

85 There is no evidence-based treatment, but various systemic immunomodulating t

86 is similar to historic rates with interferon-based treatment, but with shorter treatment duration and

87 Guideline-based treatment can improve outcomes in AF.

88 his association in an independent population-based treatment cohort and explore potential confounding

89 We aimed to evaluate the guideline-based treatment costs by DAAs from the perspective of th

90 rs for disease type and grade; and how miRNA-based treatments could be used for diverse types of mali

91 line data for evaluating trends in community-based treatment coverage for childhood illnesses.

92 the requisite health status data on which to base treatment decisions would help ensure that older pa

93 utcome information is needed to inform value-based treatment decisions for advanced-stage NSCLC.

94 The increasing popularity of antibody-based treatment demands a better understanding of antibo

95 mean rank 56.6 [SEM 4.5] vs 68.3 [4.5]; rank-based treatment difference -11.7, 95% CI -24.3 to 0.96;

96 Base treatment during reclaiming could rapidly and selec

97 with scaling up multiple structured evidence-based treatments (EBTs), a transdiagnostic treatment cou

98 We study the resulting Lasso-based treatment effect estimator under the Neyman-Rubin

99 ovide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus in

100 anage both vascularized PEDs, where evidence-based treatment exists, and nonvascularized PEDs, where

101 Family-based treatment (FBT) is an evidence-based therapy for a

102 d could constitute a novel neurobiologically-based treatment for a seemingly change-resistant group o

103 This is the first evidence-based treatment for a skeletal muscle channelopathy.

104 al trials of high-dose intravenous ascorbate-based treatment for cancer.

105 Bone marrow cell (BMC)-based treatment for critical limb ischemia in diabetic p

106 Integrating evidenced-based treatment for depression with evidenced-based adhe

107 xtending behavioural activation, an evidence-based treatment for depression, to the negative symptoms

108 n conditions, showing promise as a materials-based treatment for early-stage osteoarthritis.

109 ntibody cocktail ZMapp is a promising immune-based treatment for Ebola virus disease (EVD).

110 iver Centre with known outcome to interferon-based treatment for HCV infection were evaluated.

111 t step towards a new generation of stem cell-based treatment for heart failure.

112 on system (LEAPS) technology as a new immune-based treatment for influenza virus infection in a mouse

113 behavioural therapy (CBT)-the best evidence-based treatment for insomnia-has not been tested in this

114 lled trial compared a less invasive catheter-based treatment for MR with surgery, providing an opport

115 Although urban-rural disparities in evidence-based treatment for myocardial infarction in China have

116 Mexiletine is the first evidence-based treatment for nondystrophic myotonias.

117 ffects of a nonanthracycline and trastuzumab-based treatment for patients with early-stage human epid

118 nitive processing therapy (CPT), an evidence-based treatment for posttraumatic stress disorder (PTSD)

119 Bright light therapy is an evidence-based treatment for seasonal depression, but there is li

120 WHO recommends hospital-based treatment for young infants aged 0-59 days with cl

121 offer renewed hope for development of IL-12-based treatments for cancer.

122 Boceprevir- and telaprevir-based treatments for chronic hepatitis C virus (HCV) inf

123 ained virologic response (SVR) to interferon-based treatments for chronic hepatitis C virus infection

124 hysicians' adherence with providing evidence-based treatments for coronary artery disease (CAD).

125 des a valuable opportunity to test stem cell-based treatments for dental disorders.

126 ich has the potential to advance cannabinoid-based treatments for drug addiction.

127 Cannabis-based treatments for epilepsy have generated much intere

128 k, and the increased application of evidence-based treatments for established coronary heart disease.

129 There is a conspicuous paucity of evidence-based treatments for FNS.

130 Sofosbuvir-based treatments for genotype 1 in general are not cost-

131 However, interferon-based treatments for HCV infection have significant toxi

132 nerative endodontic procedures are stem cell-based treatments for immature teeth with pulp necrosis.

133 ays suppressed by BCL6 and suggest mechanism-based treatments for lymphoma.

134 Evidence-based treatments for major depressive disorder (MDD) are

135 Evidence-based treatments for metastatic, human epidermal growth

136 The promise of evidence-based treatments for morphea in the near future will pro

137 ct should be considered when designing IGF-1-based treatments for neurodegenerative diseases.

138 reclinical evaluation of potential stem cell-based treatments for osteoarthritis through novel approa

139 omized clinical trials have studied evidence-based treatments for OVC in low-resource settings.

140 d may be a suitable adjuvant in nanoparticle-based treatments for PDAC.

141 who have poor adherence to existing evidence-based treatments for posttraumatic stress disorder (PTSD

142 Evidence-based treatments for posttraumatic stress disorder (PTSD

143 ed and emerging pharmacotherapies and device-based treatments for posttraumatic stress disorder that

144 as been reached in the development of taxane-based treatments for prostate cancer, this study was und

145 s article offers (a) an overview of evidence-based treatments for PTSD, (b) a description of a transl

146 c kidney disease, but there are few evidence-based treatments for reducing cardiovascular events in t

147 l and efficient development of new glutamate-based treatments for SCZ.

148 s the focus of attempts to develop mechanism-based treatments for tauopathies.

149 ion by age 18 years yet few receive evidence-based treatments for their depression.

150 p inform the development of novel, mechanism-based treatments for trauma-related psychopathology.

151 paper, we discuss the evolution of catheter-based treatment from first-generation thrombectomy devic

152 vinyl substituted bis-propargyl ethers upon base treatment generally form phthalans via the Garratt-

153 Thiazide-based treatment gives less cardiovascular protection in

154 rsus historic patients who had undergone tPE-based treatment (group B, n = 56).

155 for comparative studies to provide evidence-based treatment guidance for biologic agents in rheumato

156 Evidence-based treatment guidelines are not available for primary

157 RATIONALE: The development of evidence-based treatment guidelines for pediatric pulmonary arter

158 Adherence to evidence-based treatment guidelines has been proposed as a measur

159 Adherence to evidence-based treatment guidelines in rectal cancer is suboptima

160 rent treatment practices lag behind evidence-based treatment guidelines.

161 s on meta-analyses and contemporary evidence-based treatment guidelines.

162 dgment in situations not covered by evidence-based treatment guidelines.

163 Those on HAART and protease inhibitor (PI)-based treatment had significantly higher Lp-PLA2 mass an

164 Evidence-based treatment has led to dramatic improvement in the p

165 wever, among patients with non-APL AML, ATRA-based treatment has not been effective.

166 ieve adequate disease control with rituximab-based treatment have few treatment options and a poor pr

167 individuals infected and current interferon-based treatment having toxic side effects and marginal e

168 cy of a patient strongly influences evidence-based treatment in acute myocardial infarction.

169 tive improvement in vision after bevacizumab-based treatment in children with OPGs.

170 voluntary recipients of intensive community-based treatment in New York City and in five counties el

171 because of high levels of empirical-evidence-based treatment in smear-negative patients.

172 liferative disorder (PTLD) after a rituximab-based treatment in the allogeneic hematopoietic stem cel

173 Peg-IFN-based treatment induced a stronger decrease in the HBV R

174 dicaid compose the backbone of the community-based treatment infrastructure for Medicaid enrollees.

175 In the present study, we found that a miRNA-based treatment inhibiting miRNA-34a (miR-34a) was more

176 Lifestyle modification/behavior-based treatment interventions in youth with severe obesi

177 Parent-based treatment is a viable model to provide weight loss

178 Ultraviolet (UV)-based treatment is commonly used to augment chlorination

179 Sofosbuvir-based treatment is cost-effective for incarcerated perso

180 Interferon-based treatment is not suitable for many patients with h

181 riability in patient outcome after rituximab-based treatment is partly explained by rituximab concent

182 Protease-inhibitor-based treatment is recommended as first-line for infants

183 Failure of interferon (IFN)-alpha-based treatment is related to host immunity.

184 Cisplatin-based treatment is the first line chemotherapy for sever

185 o fail directly-acting antiviral agent (DAA)-based treatment is unknown.

186 ations, the identification of a generic gene-based treatment is urgently needed.

187 e goal of reliably delivering effective gene-based treatments is now in sight.

188 cluded were randomized trials comparing shoe-based treatments (lateral heel wedge insoles or shoes wi

189 In addition to cornea-based treatment, long-term studies of a hyperopic phakic

190 osocial problems, for which we have evidence-based treatments, many patients still do not receive ade

191 lue to drug and nondrug rewards, novel brain-based treatments may finally be on the horizon.

192 Innovative behavior-based treatment, minimally invasive procedures, and medi

193 Photodynamic therapy (PDT) is a light-based treatment modality that has exhibited safety and e

194 a mineralocorticoid receptor (MR) antagonist-based treatment model to reduce cardiovascular risk in p

195 Base treatment of the N-tosylated products provides an e

196 rated with a Rose Bengal sensitiser, for SDT-based treatment of a pancreatic cancer model (BxPc-3) in

197 Algorithm-based treatment of acne by primary care clinicians may e

198 first systematic report on cyclophosphamide-based treatment of acute AMR based on modern diagnostics

199 n support of IL1RAP as a target for antibody-based treatment of AML.

200 urs slowly and limits the potential for cell-based treatment of demyelinating disease.

201 MSC1-based treatment of established tumors in an immune compe

202 recommendations to provide ART prior to IFN-based treatment of HCV and may provide insights into the

203 Current interferon alpha-based treatment of hepatitis C virus (HCV) infection fai

204 rdiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholest

205 Whereas supplement-based treatment of MAM was found to be more effective th

206 additional option for approaching community-based treatment of mental health problems.

207 that CD46 is a promising target for antibody-based treatment of multiple myeloma, especially in patie

208 c that may have beneficial effects in L-DOPA-based treatment of Parkinson patients by inhibiting L-DO

209 etic resonance (MR) cholangiopancreatography-based treatment of patients with possible choledocholith

210 Long-term efficacy of catheter-based treatment of persistent atrial fibrillation is uns

211 on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody

212 mutational scanning data using a likelihood-based treatment of the mutation counts.

213 thway as a potential target for novel immune-based treatments of chronic fungal disease.

214 elegant way to increase the efficacy of cell-based treatments of inflammatory brain diseases.

215 seful strategy for improving reconsolidation-based treatments of traumatic memories associated with a

216 expression reflected the effect of platinum-based treatment on tumor burden.

217 A transcatheter-based treatment option for severe TR appears safe and fe

218 syndrome and there are very limited evidence-based treatment options available.

219 s challenging because there are few evidence-based treatment options, and pulmonary vasodilator thera

220 ing capabilities constitute potential immune-based treatments or prophylaxis against hepatitis C viru

221 entions were screening followed by guideline-based treatment, or no screening.

222 p booklet), gastroenterologist-led algorithm-based treatment, or nurse-led algorithm-based treatment.

223 However, parent-based treatment (PBT), which is provided to the parent w

224 e potential to enable comprehensive evidence-based treatment plans to be implemented quickly, rather

225 s is the first study to examine neuroimaging-based treatment prediction in SAD.

226 h, development, and application of novel LPM-based treatment processes.

227 change strategies for PACs as used in family-based treatment programs and to provide a resource list.

228 inherent or acquired resistance to platinum-based treatments, prompting the search for new compounds

229 n under a novel, donor bone marrow (BM) cell-based treatment protocol ("Pittsburgh protocol").

230 High-quality evidence supporting a community-based treatment protocol for children with severe acute

231 Our data suggest that this BM cell-based treatment protocol is safe, is well tolerated, and

232 and can be used to inform novel biologically based treatment protocols for patients with medulloblast

233 ences from placebo exceeded the MID, and ICS-based treatments provided the greatest improvements.

234 ility were randomized to different community-based treatment providers trained to provide rectal arte

235 etween patients who had received a rituximab-based treatment (R+ group) and those who had not (R- gro

236 nt reports highlight gaps between guidelines-based treatment recommendations and evidence from clinic

237 etween intraarterial DSA- and MR angiography-based treatment recommendations was substantial (kappa =

238 MRI-based treatment recommendations were compared against fi

239 onic HCV infection who started an interferon-based treatment regimen between 1990 and 2003, following

240 tigated the use of sirolimus- and everolimus-based treatment regimens in de novo renal transplantatio

241 We observed a high rate of SVR 12 with SOF-based treatment regimes, however probably due to the hig

242 Cell-based treatment represents a new generation in the evolu

243 After failure to achieve SVR with TVR-based treatment, resistant variants are observed in most

244 .09) for patients receiving NNRTI- and LPV/r-based treatment, respectively.

245 PET-based treatment response assessment typically measures t

246 Quantification and classification of PET-based treatment response in individual patients were str

247 dual patient PET responses, selection of PET-based treatment response measures and their associated t

248 PET-based treatment response studies typically measure the c

249 arameters, overall survival (OS), and RECIST-based treatment response were tested by Cox and logistic

250 the quantification and classification of PET-based treatment response.

251 Bortezomib-based treatment resulted in a strong decrease of renal d

252 xamination), after one cycle of anthracyline-based treatment (second examination), between the anthra

253 proximal, large-vessel occlusions, IA device-based treatment should be initiated in patients with sma

254 Evidence-based treatments should be available to these individual

255 clobutane ring was able to tolerate acid and base treatments showing good chemical stability.

256 mpered the clinical translation of microglia-based treatments shown to be effective in animal disease

257 h prospective testing, the insula metabolism-based treatment-specific biomarker defined in this study

258 line IPI are the most cost-effective, immune-based treatment strategies for metastatic melanoma.

259 cule inhibitors, chemotherapeutics, and cell-based treatment strategies have been developed and inves

260 (epidermal growth factor receptor) antibody based treatment strategies have been successfully implem

261 coring the continued unmet need for evidence-based treatment strategies in HFpEF.

262 g risk to patients and when determining risk-based treatment strategies.

263 post-revascularization patients, an ischemia-based treatment strategy did not alter mortality.

264 pt for repurposing mibefradil as a mechanism-based treatment strategy for GBM.

265 Inclusion of low-dose prednisone in an MTX-based treatment strategy for tight control in early RA i

266 ow NRM risk possibly benefiting from an HSCT-based treatment strategy.

267 A PET-based treatment stratification is applicable clinically

268 During boceprevir- and telaprevir-based treatment, subjects with detectable/BLOQ HCV RNA h

269 ymorphism was evaluated regarding interferon-based treatment success and fibrosis progression after L

270 and sooner, than those treated with evidence-based treatments such as methadone, suggesting that CDDC

271 and sooner, than those treated with evidence-based treatments such as methadone, suggesting that CDDC

272 clinicians should offer or arrange evidence-based treatment, such as medication-assisted treatment w

273 could be significantly reduced by bortezomib-based treatment, suggesting that long-term administratio

274 ould be considered in the design of H(2)O(2)-based treatment systems.

275 In the mid- 1990s, a pacemaker-based treatment termed cardiac resynchronization therapy

276 ly had lower rates of response to interferon-based treatment than patients of other races.

277 attempt to quit and connect them to evidence-based treatment that includes pharmacotherapy and behavi

278 Evidence-based treatments that achieve optimal energy intake and

279 patients do not achieve SVR with telaprevir-based treatment, their viral population is often signifi

280 ung age would not have met current guideline-based treatment thresholds for statin therapy prior to t

281 er registries are needed to provide evidence-based treatments to improve in-hospital outcome.

282 l health specialists following a measurement-based treatment-to-target approach, are significantly mo

283 , 46 years), screening followed by guideline-based treatment (using boceprevir as the direct-acting a

284 accessibility and acceptability of evidence-based treatments vary, and patients may seek a variety o

285 Parent-based treatment was as effective on child weight loss an

286 sustained virological response to interferon-based treatment was associated with lower all-cause mort

287 led prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with spor

288 The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrh

289 e needing treatment, but in whom fludarabine-based treatment was not possible.

290 A strategy-learning-based treatment was used as a cognitive remediation ther

291 s who responded to multiple cycles of platin-based treatment were more likely to carry somatic BRCA1/

292 In China, evidence-based treatments were provided less often in 2001 in rur

293 reviewed to identify the effect of community-based treatment when returning inmates into the general

294 intervention facilitates access to evidence-based treatment, which typically is less available to pe

295 important with the switch from chemotherapy-based treatments, which trade control of CLL with furthe

296 biomarker studies indicate that bevacizumab-based treatment-while reducing blood flow, volume, and p

297 it has become increasingly evident that drug-based treatments will not lead to a functional or steril

298 lus lifestyle modification), medical therapy-based treatment with revascularization only for patients

299 better care for allergies based on guideline-based treatment would allow Europe's economy substantial

300 sed DSA clearance compared with historic tPE-based treatment, yet spontaneous clearance of new DSA al